Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [177Lu]Lu-PSMA-617 radioligand therapy.

about

Targeted α-therapy of prostate cancer using radiolabeled PSMA inhibitors: a game changer in nuclear medicine

P2860

Q57107703-4D309F35-714D-44CF-88C5-7EE813A9AE3A

P2860

Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [177Lu]Lu-PSMA-617 radioligand therapy.

Item

http://www.wikidata.org/entity/Q47158291

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Predictors of overall survival ...... -PSMA-617 radioligand therapy.

@en

Predictors of overall survival ...... -PSMA-617 radioligand therapy.

@nl

type

Item

label

Predictors of overall survival ...... -PSMA-617 radioligand therapy.

@en

Predictors of overall survival ...... -PSMA-617 radioligand therapy.

@nl

prefLabel

Predictors of overall survival ...... -PSMA-617 radioligand therapy.

@en

Predictors of overall survival ...... -PSMA-617 radioligand therapy.

@nl

P1476

Predictors of overall survival ...... u-PSMA-617 radioligand therapy

@en

P2093

Carl Schlenkhoff

http://www.w3.org/2001/XMLSchema#string

Florian C Gaertner

http://www.w3.org/2001/XMLSchema#string

Markus Essler

http://www.w3.org/2001/XMLSchema#string

Rolf Fimmers

http://www.w3.org/2001/XMLSchema#string

Stefan Hauser

http://www.w3.org/2001/XMLSchema#string

Stefan Hirzebruch

http://www.w3.org/2001/XMLSchema#string

Stephan Schlolaut

http://www.w3.org/2001/XMLSchema#string

Zool Hilmi Awang

http://www.w3.org/2001/XMLSchema#string

P2860

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

Alpha emitter radium-223 and survival in metastatic prostate cancer

Increased survival with enzalutamide in prostate cancer after chemotherapy

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients.

Radioligand therapy of metastatic prostate cancer using 177Lu-PSMA-617 after radiation exposure to 223Ra-dichloride.

The Role of Positron Emission Tomography With (68)Gallium (Ga)-Labeled Prostate-specific Membrane Antigen (PSMA) in the Management of Patients With Organ-confined and Locally Advanced Prostate Cancer Prior to Radical Treatment and After Radical Pros

177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer.

Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study.

Radioligand Therapy With 177Lu-PSMA-617 as A Novel Therapeutic Option in Patients With Metastatic Castration Resistant Prostate Cancer.

P304

103108-103116

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.21600

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Hojjat Ahmadzadehfar

Anna Yordanova

P577

2017-10-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29262549

http://www.w3.org/2001/XMLSchema#string

P932

5732715

http://www.w3.org/2001/XMLSchema#string

Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [177Lu]Lu-PSMA-617 radioligand therapy.

about

P2860

P2860

Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [177Lu]Lu-PSMA-617 radioligand therapy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932